Introduction You manage royalty streams representing 40-80% of your biotech company’s total revenue, the golden thread connecting innovation to commercial success. But one reporting error, one partner dispute, or one delayed reconciliation could unravel...
Introduction You operate at the intersection of sophisticated hardware, cutting-edge software, and complex service ecosystems, where one IFRS 15 misstep could trigger the restatement that destroys your credibility forever. Your medtech business model blends...
Introduction You just received a €50 million upfront payment for your breakthrough licensing deal. The CEO is celebrating, investors are thrilled, but you know the truth; incorrectly accounting for this payment could trigger the restatement that ends your...
Introduction You are managing milestone payments worth hundreds of millions of euros, the lifeblood of your life sciences partnerships. But one wrong accounting decision on these critical payments could trigger the restatement that ends your reputation as a...
Introduction IAS 38 is a key International Financial Reporting Standard that governs the accounting for intangible assets. It outlines essential principles for recognising, measuring, and disclosing these assets, which can significantly impact financial statements. In...
You are navigating pharmaceutical licensing deals worth billions of euros annually, transactions that fuel innovation and expand markets for breakthrough therapies. Yet you face a challenge that demands both technical precision and strategic insight: applying IFRS 15...
